Daratumumab for autoimmune diseases: a systematic review
Objective Refractory autoimmune diseases remain a significant challenge in clinical practice and new therapeutic options are needed. This systematic review evaluates the existing reported data on the CD38-targeting antibody daratumumab as a new therapeutic approach in autoantibody-mediated autoimmun...
Saved in:
Main Authors: | Martin Krusche, Ina Kötter, Lennard Ostendorf, Nikolas Ruffer, Marie-Therese Holzer, Tobias B. Huber |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-12-01
|
Series: | RMD Open |
Online Access: | https://rmdopen.bmj.com/content/9/4/e003604.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Daratumumab improves the hematological response and kidney function of patients with light chain deposition disease
by: Xin Zhang, et al.
Published: (2025-01-01) -
Refractory IgD Multiple Myeloma Treated with Daratumumab: A Case Report and Literature Review
by: Muhammad Husnain, et al.
Published: (2016-01-01) -
Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01) -
Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature
by: Matthew Lee, et al.
Published: (2022-01-01) -
Insulin Autoimmune Syndrome: A Systematic Review
by: MingXu Lin, et al.
Published: (2023-01-01)